On the evening of October 25, BYHEALTH (300146.SZ) announced its performance report for the first three quarters in 2022. According to the report, BYHEALTH recorded a revenue of RMB 6.16 billion and a net profit of RMB 1.482 billion (attributable to shareholders of the listed company) for the first three quarters.

Maintaining a Leading Position while Exploring Opportunities for Multiple Categories

According to the report, probiotics products have impressive performance. The revenue from sales of Life-Space products in China was RMB 253 million, a year-on-year growth of 53.33%. The overseas operating revenue of Life-Space Group Pty Ltd (LSG) was AUD 124 million, a year-on-year growth of 21.71%. In recent years, probiotics products have achieved high growth in multiple channels. In the first quarter this year, probiotics products even ranked among the top 3 on Alibaba. The company will maintain bullish on the probiotic supplements and promote further marketing. In addition, with its product strategy of hero products, image products and star products, BYHEALTH is now making active efforts to further explore opportunities for more categories.

Remarkable Scientific Achievement and Focus on Transformation into a Strong Technology-based Company

At the beginning of 2022, BYHEALTH announced that the company would “transform into a strong technology-based company in eight years” and focus on building product power with “hard technology” and science and technology competitiveness by continuing diving into such fields as new materials, technologies and functions. In the first half of 2022, the company, jointly with well-known universities and research institutions in China, published results of several prospective fundamental research on anti-aging, including the world’s first* study of association of NAD⁺ contents with aging in Chinese population and the study of NAD⁺ levels in female.

During the reporting period, the company made remarkable scientific achievements and published articles on independent probiotics strain development, the new mechanism of water-soluble tomato concentrate and other fields, attracting much attention from the industry. In August, BYHEALTH Institute of Nutrition and Health announced its latest achievement: the Lactobacillus Paracasei LPB27, a fine intestinal strain co-developed with West China School of Public Health and other influential institutes after 7 years of effort. The strain has been licensed two national invention patents and the related research results have been covered by well-known media. Currently, the patent strain has been applied as the main strain material in the new “60 billion probiotics” product of Life-Space. In September, BYHEALTH Institute of Nutrition and Health, Institute of Chinese Materia Medica jointly published their latest research results regarding water-soluble tomato concentrate on the authoritative scientific journal - Frontiers in Nutrition. The research revealed the new mechanism of water-soluble tomato concentrate in modulating blood flow and marks a new step in research and development of new function.

In the future, BYHEALTH will roll out more new products with multiple functions, develop new materials, and apply new technologies to support the development of the nutrition and health industry. With the promotion of “science-based nutrition” strategy, the company is steadily moving towards a strong technology-based company.

*Note: World’s first study of association of NAD+ contents with aging - data as of March 31, 2022, from five authoritative academic literature search platforms (CNKI, Wanfang, PubMed, Web of Science, and Elsevier ScienceDirect).